10x Genomics (NASDAQ:TXG) Receives $15.96 Average Target Price from Analysts

10x Genomics (NASDAQ:TXG) has earned an average recommendation of “Hold” from the eighteen analysts that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $16.30.

A number of brokerages have issued reports on TXG. Morgan Stanley restated an “equal weight” rating and set a $20.00 target price (up previously from $17.00) on shares of 10x Genomics in a report on Monday, December 1st. JPMorgan Chase & Co. lifted their price objective on shares of 10x Genomics from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Citigroup cut shares of 10x Genomics from a “buy” rating to a “cautious” rating in a report on Thursday, December 11th. TD Cowen increased their target price on shares of 10x Genomics from $15.00 to $18.00 and gave the stock a “hold” rating in a report on Wednesday, January 7th. Finally, Wall Street Zen cut shares of 10x Genomics from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th.

10x Genomics Stock Performance

TXG opened at $19.80 on Friday. The company has a fifty day moving average price of $17.02 and a two-hundred day moving average price of $14.35. The firm has a market capitalization of $2.51 billion, a PE ratio of -31.93 and a beta of 2.18. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $21.18.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.05. 10x Genomics had a negative return on equity of 11.50% and a negative net margin of 11.89%.The company had revenue of $149.00 million for the quarter, compared to the consensus estimate of $142.50 million. During the same quarter in the prior year, the business posted ($0.30) EPS. The firm’s quarterly revenue was down 1.7% on a year-over-year basis. Equities analysts forecast that 10x Genomics will post -1.43 EPS for the current year.

10x Genomics News Roundup

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Company raised revenue guidance that tops Street estimates for both Q4 and FY‑2025 (Q4 revenue guided at ~$166.0M vs. consensus ~$155.9M; FY revenue guided at ~$642.8M vs. consensus ~$632.6M), signaling stronger demand than expected. 10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Multiple scientific and commercial partnerships and initiatives launched that broaden addressable markets and validate platform utility — includes a Dana‑Farber collaboration to advance tumor single‑cell/spatial diagnostics, a blood‑based autoimmune diagnostics study, and a large Cancer Research Institute AI-driven immuno‑oncology initiative using 10x technology. These could drive longer‑term recurring revenue and diagnostic development opportunities. 10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling 10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease Cancer Research Institute Launches Transformative AI-Driven Immuno-Oncology Initiative Powered by 10x Genomics Technology
• Neutral Sentiment: Street reaction mixed — William Blair maintained a Hold rating citing balanced risk/reward despite solid execution, which tempers upside from the guidance beat. Balanced Risk/Reward Keeps 10x Genomics at Hold Despite Solid Execution and Discounted Valuation
• Neutral Sentiment: Reported short‑interest data in the update appears anomalous (shows zero shares), so there’s no clear short squeeze or covering signal to explain intraday moves.
• Negative Sentiment: Underlying fundamentals remain mixed: recent quarterly revenue was slightly down year‑over‑year and the company remains unprofitable (negative margins and expected negative EPS for the year), which keeps valuation and sentiment constrained despite revenue beats.

Insider Buying and Selling

In other 10x Genomics news, CEO Serge Saxonov sold 13,261 shares of 10x Genomics stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $251,959.00. Following the transaction, the chief executive officer directly owned 1,021,556 shares in the company, valued at approximately $19,409,564. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Benjamin J. Hindson sold 8,283 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $19.00, for a total value of $157,377.00. Following the completion of the transaction, the insider directly owned 432,605 shares of the company’s stock, valued at approximately $8,219,495. The trade was a 1.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 33,432 shares of company stock valued at $635,208. 10.03% of the stock is owned by company insiders.

Hedge Funds Weigh In On 10x Genomics

Several institutional investors and hedge funds have recently modified their holdings of the business. Allworth Financial LP raised its holdings in 10x Genomics by 150.4% during the 2nd quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock worth $26,000 after buying an additional 1,364 shares during the period. True Wealth Design LLC increased its position in shares of 10x Genomics by 1,552.5% during the second quarter. True Wealth Design LLC now owns 3,586 shares of the company’s stock worth $42,000 after acquiring an additional 3,369 shares in the last quarter. Abich Financial Wealth Management LLC bought a new stake in shares of 10x Genomics during the third quarter worth $56,000. Blue Trust Inc. raised its holdings in shares of 10x Genomics by 48.1% during the second quarter. Blue Trust Inc. now owns 4,894 shares of the company’s stock worth $57,000 after acquiring an additional 1,590 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its position in 10x Genomics by 203.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock valued at $87,000 after acquiring an additional 5,025 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors and hedge funds.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.